Medical Condition News

RSS

Positive preliminary results from CytRx bafetinib Phase 2 trial for relapsed B-cell chronic lymphocytic leukemia

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that preliminary results from its ENABLE Phase 2 proof-of-concept trial demonstrated that bafetinib, the Company's Bcr-Abl, Lyn and Fyn kinase inhibitor, was clinically active in a group of patients with relapsed or refractory B-cell chronic lymphocytic leukemia (B-CLL) who have failed several other treatments for their cancer.

13 Jun 2011

New tool to rapidly assess risk of aggressive, violent behavior by children and adolescents

Researchers at Cincinnati Children's Hospital Medical Center have developed a tool to rapidly assess the risk of aggressive and violent behavior by children and adolescents hospitalized on psychiatric units. Ultimately, they hope to use the questionnaire to improve treatment and prevention of aggressive behavior in schools and in the community.

13 Jun 2011

Daytime sleepiness influences brain's response to food and affects eating behavior

Daytime sleepiness may affect inhibitory control in the brain when viewing tantalizing, high-calorie foods, suggests a research abstract that will be presented Monday, June 13, in Minneapolis, Minn., at SLEEP 2011, the 25th Anniversary Meeting of the Associated Professional Sleep Societies LLC (APSS).

13 Jun 2011

Study reveals positive impact of Soliris on long-term outcomes in PNH patients

Alexion Pharmaceuticals, Inc. today announced the presentation of research that provides further insight into the clinical consequences of paroxysmal nocturnal hemoglobinuria (PNH), and positive impact of Soliris® (eculizumab) therapy on long-term outcomes.

13 Jun 2011

New drug more effective than standard treatment to prevent heart-attack deaths

Robert Storey, Professor of Cardiology at the University of Sheffield's Department of Cardiovascular Science, presented findings today that confirm one in five deaths in the year following a heart attack could be prevented if a new drug, ticagrelor, was used instead of the standard treatment, clopidogrel.

13 Jun 2011

Survey reveals increase in drinking, cannabis use and psychological distress

The latest survey of Ontario adults from the Centre for Addiction and Mental Health (CAMH) shows increasing rates of daily drinking and cannabis use and high levels of psychological distress. The results of the 2009 CAMH Monitor survey, the longest running survey tracking mental health and addiction indicators among adults in Ontario, were published today.

13 Jun 2011

CEL-SCI initiates Multikine Phase III clinical trial for head and neck cancer in Hungary

CEL-SCI Corporation announced today that it has commenced its Phase III clinical trial for Multikine®, the Company's flagship immunotherapy, at the National Institute of Oncology in Budapest, Hungary. Enrollment is expected to start soon in this center. The study is already ongoing at twelve clinical sites in the United States, Canada, Poland and India.

13 Jun 2011

Sarcoma UK releases inspiring film about people's experiences of living with bone cancer

Sarcoma UK releases an inspiring film about the experiences of people living with a rare form of cancer of soft tissue and bone, as part of Sarcoma Awareness Week.

13 Jun 2011

Trimeris, Synageva enter definitive merger agreement

Synageva BioPharma Corp., a privately held biopharmaceutical company developing therapeutic products for rare disorders, and Trimeris, Inc., announced today that they have entered into a definitive agreement under which Synageva will merge with Trimeris in an all-stock transaction.

13 Jun 2011

Servier, Cortex sign new option agreement for AMPAKINE technology

Cortex Pharmaceuticals, Inc. entered into a new agreement with Servier to sell its remaining rights to the jointly discovered high impact AMPAKINE compound, CX1632.

13 Jun 2011

Patients with multiple sclerosis can benefit from group therapy sessions

Offering Multiple Sclerosis sufferers emotional support through group therapy sessions could improve their quality of life and save the NHS almost £500 per patient, a study at The University of Nottingham has discovered.

13 Jun 2011

Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today reported results from two ongoing Phase I studies with MLN9708, the first oral proteasome inhibitor being studied in patients with relapsed and/or refractory multiple myeloma.

13 Jun 2011

Toshiba to highlight cardiac ultrasound applications at ASE annual meeting

Ultrasound is often used as a first-line diagnostic exam to quickly and safely diagnose a range of patient conditions. At this year's American Society of Echocardiography (ASE) annual meeting in Montreal, June 11-14, 2011, Toshiba America Medical Systems, Inc., will highlight cardiac and shared service ultrasound applications designed to improve cardiac ultrasound imaging.

13 Jun 2011

Circassia announces ToleroMune vaccine phase II trial results against cat allergy

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the results of a phase II clinical trial showing that patients who received four doses of its ToleroMune cat allergy vaccine over a 12-week period maintained a statistically significant reduction in symptoms one year later.

13 Jun 2011

Researchers to examine risks and benefits of blood transfusions

Risks associated with blood transfusions are to be scrutinized in a new national project that will inform public policy on the process.

13 Jun 2011

UC Davis, Jackson Laboratory and NCI partner for human clinical trials on cancer

About nine out of 10 new cancer drugs successfully clear preclinical development hurdles, but then they fail in human clinical testing. A new partnership facilitated by SAIC-Frederick Inc. aims to help change that outcome.

13 Jun 2011

Left ventricular assist device increases incidence of internal bleeding in heart failure patients

The incidence of internal bleeding was higher in the most commonly implanted heart device than in an earlier model, according to two studies at Henry Ford Hospital in Detroit.

13 Jun 2011

Risky behavior, psychiatric disorders and substance abuse contribute to opioid overdose

Deaths related to prescription opioid therapy are under intense scrutiny, prompting those in pain medicine-clinicians, patient advocates, and regulators-to understand the causes behind avoidable mortality in legitimately treated patients.

13 Jun 2011

Second course of treatment could cure head and neck cancer

A new study has determined predictors that can better identify patients who will benefit from a potentially toxic second course of treatment, which offers a small but real chance of cure in select patients with head and neck cancer.

13 Jun 2011

FDA approves Valeant's Potiga Tablets for treatment of partial-onset seizures

Valeant Pharmaceuticals International, Inc. and GlaxoSmithKline announced today that the U.S. Food and Drug Administration (FDA) has approved Potiga Tablets, a potassium channel opener, as adjunctive treatment of partial-onset seizures in patients aged 18 years and older.

13 Jun 2011

Medical Condition News

Positive preliminary results from CytRx bafetinib Phase 2 trial for relapsed B-cell chronic lymphocytic leukemia

New tool to rapidly assess risk of aggressive, violent behavior by children and adolescents

Daytime sleepiness influences brain's response to food and affects eating behavior

Study reveals positive impact of Soliris on long-term outcomes in PNH patients

New drug more effective than standard treatment to prevent heart-attack deaths

Survey reveals increase in drinking, cannabis use and psychological distress

CEL-SCI initiates Multikine Phase III clinical trial for head and neck cancer in Hungary

Sarcoma UK releases inspiring film about people's experiences of living with bone cancer

Trimeris, Synageva enter definitive merger agreement

Servier, Cortex sign new option agreement for AMPAKINE technology

Patients with multiple sclerosis can benefit from group therapy sessions

Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma

Toshiba to highlight cardiac ultrasound applications at ASE annual meeting

Circassia announces ToleroMune vaccine phase II trial results against cat allergy

Researchers to examine risks and benefits of blood transfusions

UC Davis, Jackson Laboratory and NCI partner for human clinical trials on cancer

Left ventricular assist device increases incidence of internal bleeding in heart failure patients

Risky behavior, psychiatric disorders and substance abuse contribute to opioid overdose

Second course of treatment could cure head and neck cancer

FDA approves Valeant's Potiga Tablets for treatment of partial-onset seizures

CoppaFeel!: Breast Cancer Doesn’t Discriminate, So Why Should Awareness?

The CAR T Veteran: A Journey of Resilience, Remission, and Advocacy

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Latest News